Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Hartkopf A, Michel LL, Wallwiener M, Fasching PA, Tauber N

Open source

DOI
10.1007/s10549-026-07939-z
Published
2026 Apr 2
Container
Breast cancer research and treatment
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10549-026-07939-z,
  title = {Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.},
  author = {Hörner M and Tretschock LM and John N and Ziegler P and Häberle L and Uhrig S and Goossens C and Amann N and Cieslik JP and Dannehl D and Deutsch TM and Dimpfl M and Ehlert M and Eichstädt K and Englisch A and Köpke MB and Krückel A and Link T and Müller A and Reinhardt K and Roth J and Schäffler H and Sych L and Tegeler CM and Wichmann C and Banys-Paluchowski M and Princk H and Rody A and Brucker SY and Ditsch N and Ettl J and Fehm T and Hack CC and Hadji P and Hein A and Janni WW and Kolberg HC and Lüftner D and Lux MP and Müller V and Schneeweiss A and Taran FA and Tesch H and Wallwiener D and Marmé F and Seitz S and Belleville E and Hartkopf A and Michel LL and Wallwiener M and Fasching PA and Tauber N},
  year = {2026},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-026-07939-z},
  url = {https://doi.org/10.1007/s10549-026-07939-z}
}

RIS

TY  - JOUR
TI  - Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.
AU  - Hörner M
AU  - Tretschock LM
AU  - John N
AU  - Ziegler P
AU  - Häberle L
AU  - Uhrig S
AU  - Goossens C
AU  - Amann N
AU  - Cieslik JP
AU  - Dannehl D
AU  - Deutsch TM
AU  - Dimpfl M
AU  - Ehlert M
AU  - Eichstädt K
AU  - Englisch A
AU  - Köpke MB
AU  - Krückel A
AU  - Link T
AU  - Müller A
AU  - Reinhardt K
AU  - Roth J
AU  - Schäffler H
AU  - Sych L
AU  - Tegeler CM
AU  - Wichmann C
AU  - Banys-Paluchowski M
AU  - Princk H
AU  - Rody A
AU  - Brucker SY
AU  - Ditsch N
AU  - Ettl J
AU  - Fehm T
AU  - Hack CC
AU  - Hadji P
AU  - Hein A
AU  - Janni WW
AU  - Kolberg HC
AU  - Lüftner D
AU  - Lux MP
AU  - Müller V
AU  - Schneeweiss A
AU  - Taran FA
AU  - Tesch H
AU  - Wallwiener D
AU  - Marmé F
AU  - Seitz S
AU  - Belleville E
AU  - Hartkopf A
AU  - Michel LL
AU  - Wallwiener M
AU  - Fasching PA
AU  - Tauber N
PY  - 2026
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-026-07939-z
UR  - https://doi.org/10.1007/s10549-026-07939-z
ER  -

APA

M, H., LM, T., N, J., P, Z., L, H., S, U., C, G., N, A., JP, C., D, D., TM, D., M, D., M, E., K, E., A, E., MB, K., A, K., T, L., A, M., K, R., J, R., H, S., L, S., CM, T., C, W., M, B., H, P., A, R., SY, B., N, D., J, E., T, F., CC, H., P, H., A, H., WW, J., HC, K., D, L., MP, L., V, M., A, S., FA, T., H, T., D, W., F, M., S, S., E, B., A, H., LL, M., M, W., PA, F., & N, T. (2026). Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-07939-z

Source records